Table 1.
Patients’ characteristics.
| Variable | Control group N = 9 |
PFD group N = 9* |
|---|---|---|
| Sex | ||
| Male/female | 9/0 | 6/3 |
| Age, y, median (range) | 74.7 (67–82) | 71.9 (60–82) |
| Histological ILD type | ||
| UIP | 5 | 7 |
| DIP | 1 | 0 |
| Unknown | 3 | 2 |
| Cancer type* | ||
| Adenocarcinoma | 2 | 3 |
| Squamous cell carcinoma | 7 | 8 |
| p-Stage* | ||
| IA/IB/IIA/IIB/IIIA | 0/3/4/1/1 | 7/2/0/1/1 |
| Operative method | ||
| Lobectomy | 8 | 4 |
| Segmentectomy | 1 | 2 |
| Wedge resection | 0 | 3 |
| AE-ILD | ||
| Yes/no | 1/8 | 1/8 |
| Survival (months) | 17.9 | 15.0 |
| Outcome | ||
| Alive | 3 | 6 |
| Alive with disease | 1 | 0 |
| Dead of cancer | 3 | 2 |
| Dead of respiratory failure | 1 | 1 |
| Dead of other diseases | 1 | 0 |
PFD pirfenidone, ILD interstitial lung disease, UIP usual interstitial pneumonia, DIP desquamative interstitial pneumonia, AE adverse event.
*Two of 9 PFD-Group patients had double tumors.